Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C round brings in $15.5mm for Bonti

Executive Summary

Bonti Inc. (neurotoxins for aesthetic and therapeutic indications) closed a $15.5mm Series C financing round from undisclosed new and returning investors. The 2015 start-up will use the proceeds for market research and to fund continued development of lead compound EB001 (botulinum neurotoxin serotype E), including completion of an ongoing Phase II study in musculoskeletal pain and preparation for an end-of-Phase II meeting with the FDA. To date the company has brought in $36.1mm through investors including RBV Capital, City Hill Ventures, Colt Ventures, JMCR Partners, and HighLight Capital.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies